In NSCLC, dysregulation in EGFR signaling can be associated with EGFR overexpression or EGFR-activating mutations (exon 19 deletion and L858R point mutation are present in 10–20% of NSCLC Caucasian patients and in 50% of Asian patients). Here, EGFR is linked to non-small cell lung carcinoma.